Condition: Adolescents With Moderate-to-severe Atopic Dermatitis · Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.
This description comes directly from the study's public registry record.
Xiaoyan Bai · +86-0518-82342973 · xiaoyan.bai.xb1@hengrui.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07309055